Table 1.
Patients‘ characteristics
| Characteristics | Patients with cancer diagnosed: | Difference (%) | P value | |
| Before lockdown (March 16, 2019 to May 31, 2019) |
During lockdown (March 16, 2020 to May 31, 2020) |
|||
| Number of patients | 594 | 342 | −42% | |
| Age, median (range) | 61.3 (21–93) | 59.4 (26–95) | 0.038* | |
| Patients with distant metastases (FIGO IV or M1) | 117 (20%) | 55 (16%) | −4% | NS† |
| Patients with early-stage disease (FIGO I or Tis/T1 and N0) | 284 (48%) | 133 (39%) | −9% | NS† |
| Breast cancer | 351 | 201 | −43% | |
| Tis | 34 (10%) | 17 (8.5%) | −1.5% | <0.001† |
| T1 | 149 (43%) | 64 (32%) | −11% | |
| T2–4 | 118 (34%) | 48 (24%) | −10% | |
| Tx (due to neoadjuvant chemotherapy) | 48 (14%) | 71 (35%) | ||
| N0 | 190 (54%) | 87 (43%) | −11% | <0.001† |
| N1-3 | 102 (29%) | 33 (16%) | −13% | |
| Nx (due to neoadjuvant chemotherapy) | 59 (17%) | 81 (40%) | ||
| Ovarian cancer | 70 | 36 | −49% | |
| FIGO I/II | 19 (27%) | 9 (25%) | −2% | NS† |
| FIGO III/IV | 51 (73%) | 27 (75%) | +2% | |
| Endometrial cancer | 77 | 51 | −34% | |
| FIGO I/II | 62 (80%) | 39 (76%) | −3% | NS† |
| FIGO III/IV | 15 (19%) | 11 (22%) | +3% | |
| Cervical cancer | 64 | 33 | −48% | |
| FIGO I/II | 44 (69%) | 28 (85%) | +17% | NS† |
| FIGO III/IV | 20 (31%) | 5 (15%) | −17% | |
| Vulvar cancer | 19 | 9 | −53% | |
| FIGO I/II | 15 (83%) | 5 (56%) | −27% | NS† |
| FIGO III/IV | 3 (17%) | 4 (44%) | +27% | |
| Uterine sarcoma | 5 | 4 | −20% | |
| Others | 8 | 8 | 0% | |
Characteristics before and after lockdown of all patients and dependent on cancer type.
*Mann-Whitney U-test.
†χ2 test.
NS, non-significant.